Laboratory of Clinical Biochemistry and Metabolism, Department of General Pediatrics, Adolescent Medicine and Neonatology, Faculty of Medicine, Medical Center-University of Freiburg, Freiburg, Germany.
Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.
Vitam Horm. 2022;119:275-298. doi: 10.1016/bs.vh.2022.02.001. Epub 2022 Mar 15.
Vitamin B (cobalamin, Cbl, B) is a water-soluble micronutrient synthesized exclusively by a group of microorganisms. Human beings are unable to make B and thus obtain the vitamin via intake of animal products, fermented plant-based foods or supplements. Vitamin B obtained from the diet comprises three major chemical forms, namely hydroxocobalamin (HOCbl), methylcobalamin (MeCbl) and adenosylcobalamin (AdoCbl). The most common form of B present in supplements is cyanocobalamin (CNCbl). Yet, these chemical forms cannot be utilized directly as they come, but instead, they undergo chemical processing by the MMACHC protein, also known as CblC. Processing of dietary B by CblC involves removal of the upper-axial ligand (beta-ligand) yielding the one-electron reduced intermediate cob(II)alamin. Newly formed cob(II)alamin undergoes trafficking and delivery to the two B-dependent enzymes, cytosolic methionine synthase (MS) and mitochondrial methylmalonyl-CoA mutase (MUT). The catalytic cycles of MS and MUT incorporate cob(II)alamin as a precursor to regenerate the coenzyme forms MeCbl and AdoCbl, respectively. Mutations and epimutations in the MMACHC gene result in cblC disease, the most common inborn error of B metabolism, which manifests with combined homocystinuria and methylmalonic aciduria. Elevation of metabolites homocysteine and methylmalonic acid occurs because the lack of an active CblC blocks formation of the indispensable precursor cob(II)alamin that is necessary to activate MS and MUT. Thus, in patients with cblC disease, vitamin B is absorbed and present in circulation in normal to high concentrations, yet, cells are unable to make use of it. Mutations in seemingly unrelated genes that modify MMACHC gene expression also result in clinical phenotypes that resemble cblC disease. We review current knowledge on structural and functional aspects of intracellular processing of vitamin B by the versatile protein CblC, its partners and possible regulators.
维生素 B(钴胺素、Cbl、B)是一种仅由一组微生物合成的水溶性微量营养素。人类无法制造 B,因此只能通过摄入动物产品、发酵植物性食品或补充剂来获得这种维生素。从饮食中获得的维生素 B 包括三种主要的化学形式,即羟钴胺素 (HOCbl)、甲基钴胺素 (MeCbl) 和腺苷钴胺素 (AdoCbl)。补充剂中最常见的 B 形式是氰钴胺素 (CNCbl)。然而,这些化学形式不能直接被利用,而是需要通过 MMACHC 蛋白(也称为 CblC)进行化学处理。CblC 对膳食 B 的处理涉及去除上轴向配体(β-配体),产生单电子还原中间产物 cob(II)alamin。新形成的 cob(II)alamin 进行运输并递送至两种 B 依赖性酶,细胞质蛋氨酸合酶 (MS) 和线粒体甲基丙二酰辅酶 A 变位酶 (MUT)。MS 和 MUT 的催化循环将 cob(II)alamin 作为前体掺入,分别再生 MeCbl 和 AdoCbl 的辅酶形式。MMACHC 基因的突变和表观突变导致 cblC 疾病,这是最常见的 B 代谢先天性错误,表现为同型胱氨酸尿症和甲基丙二酸尿症合并。由于缺乏活性 CblC 会阻止必需前体 cob(II)alamin 的形成,从而阻止 MS 和 MUT 的激活,因此代谢物同型半胱氨酸和甲基丙二酸的升高发生。因此,在 cblC 病患者中,维生素 B 被吸收并以正常至高浓度存在于循环中,但细胞无法利用它。似乎与 MMACHC 基因表达相关的基因的突变也会导致类似于 cblC 疾病的临床表型。我们回顾了多功能蛋白 CblC 及其伴侣和可能的调节剂对内源性维生素 B 处理的结构和功能方面的最新知识。
Vitam Horm. 2022
Mol Genet Metab. 2009-8-3
Acc Chem Res. 2021-4-20
J Biol Chem. 2020-7-10
Mol Genet Metab. 2011-3-24
Mol Genet Metab. 2010-2-15
Vitam Horm. 2022
Philos Trans R Soc Lond B Biol Sci. 2024-11-18
World J Diabetes. 2023-5-15